BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37739894)

  • 1. Enhanced prognosis of HCC patients undergoing radical treatments with tenofovir versus entecavir: A meta-analysis based on propensity score matching studies.
    Kong Q; Yi M; Teng F; Chen Z
    Asian J Surg; 2024 Jan; 47(1):55-62. PubMed ID: 37739894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
    Choi WM; Yip TC; Wong GL; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Cant H; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Lim YS
    J Hepatol; 2023 Mar; 78(3):534-542. PubMed ID: 36572349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
    Wang XH; Hu ZL; Fu YZ; Hou JY; Li WX; Zhang YJ; Xu L; Zhou QF; Chen MS; Zhou ZG
    J Gastroenterol; 2022 Mar; 57(3):185-198. PubMed ID: 35152312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy.
    Kao WY; Tan EC; Lee HL; Huang YH; Huo TI; Chang CC; Chiou JF; Hou MC; Wu JC; Su CW
    Aliment Pharmacol Ther; 2023 Jun; 57(11):1299-1312. PubMed ID: 36914943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
    Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection.
    Li P; Wang Y; Yu J; Yu J; Tao Q; Zhang J; Lau WY; Zhou W; Huang G
    JAMA Netw Open; 2023 Oct; 6(10):e2340353. PubMed ID: 37906195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.
    Peng W; Yi M; Qi X; Qi W; Li C; Wen T
    Trials; 2023 Dec; 24(1):781. PubMed ID: 38042834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
    Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
    BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis.
    Liu H; Han CL; Tian BW; Ding ZN; Yang YF; Ma YL; Yang CC; Meng GX; Xue JS; Wang DX; Dong ZR; Chen ZQ; Hong JG; Li T
    Expert Rev Gastroenterol Hepatol; 2023; 17(6):623-633. PubMed ID: 37148261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study.
    Qi W; Shen J; Dai J; Wu Y; Zhang Y; Leng S; Gao F; Ran S; Peng W; Zhang X; Wen T; Li C
    Cancer Med; 2021 Dec; 10(23):8421-8431. PubMed ID: 34643050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
    Yuan BH; Li RH; Huo RR; Li MJ; Papatheodoridis G; Zhong JH
    J Gastroenterol Hepatol; 2022 May; 37(5):782-794. PubMed ID: 35080052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
    Hsu YC; Wong GL; Chen CH; Peng CY; Yeh ML; Cheung KS; Toyoda H; Huang CF; Trinh H; Xie Q; Enomoto M; Liu L; Yasuda S; Tanaka Y; Kozuka R; Tsai PC; Huang YT; Wong C; Huang R; Jang TY; Hoang J; Yang HI; Li J; Lee DH; Takahashi H; Zhang JQ; Ogawa E; Zhao C; Liu C; Furusyo N; Eguchi Y; Wong C; Wu C; Kumada T; Yuen MF; Yu ML; Nguyen MH
    Am J Gastroenterol; 2020 Feb; 115(2):271-280. PubMed ID: 31634265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Choi J; Jo C; Lim YS
    Hepatology; 2021 Feb; 73(2):661-673. PubMed ID: 32324905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.
    Shen J; Qi W; Dai J; Leng S; Jiang K; Zhang Y; Ran S; Li C; Wen T
    Chin Med J (Engl); 2021 Dec; 135(3):301-308. PubMed ID: 34958539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
    Lee SW; Kwon JH; Lee HL; Yoo SH; Nam HC; Sung PS; Nam SW; Bae SH; Choi JY; Yoon SK; Han NI; Jang JW
    Gut; 2020 Jul; 69(7):1301-1308. PubMed ID: 31672838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial.
    Linye H; Zijing X; Xiaoyun Z; Zhihui L; Tianfu W; Chuan L
    Int J Surg; 2023 Oct; 109(10):3032-3041. PubMed ID: 37335984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
    Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation.
    Yang J; Chen Y; Sun H; Zhang X; Wang J; Liang Z; Fu B; Zhang T; Yi S; Deng Y; Yang Y
    Infect Agent Cancer; 2023 Jan; 18(1):2. PubMed ID: 36650583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan.
    Lin CL; Lin YL; Liang KH; Chen LW; Chien CH; Hu CC; Huang TS; Shyu YC; Yeh CT; Chien RN
    Clin Ther; 2022 Mar; 44(3):403-417.e6. PubMed ID: 35469645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.